Modulation of telomere length by oligonucleotides having a G-core sequence
AssigneeIsis Pharmaceuticals, Inc.
InventorsRonnie C. Hanecak, Kevin P. Anderson, C. Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy A. Vickers, Jacqueline R. Wyatt
Life of this patent
Estimating the term…
Abstract
Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.
Claims16
A method for inhibiting the division of a malignant mammalian cell comprising contacting said malignant mammalian cell with a chemically modified oligonucleotide having no more than about 27 nucleic acid base units, said oligonucleotide having the sequence (NxG3-4)QNX wherein X is 1 to 8 and Q is 1 to 6, wherein said oligonucleotide modulates mammalian telomere length.
A chemically modified oligonucleotide having no more than about 27 nucleic acid base units, said oligonueleotide having the sequence (NxG4)QNX wherein X is 1 to 8 and Q is 1 to 6.
A chemically modified oligonucleotide having no more than about 27 nucleic acid base units, said oligonucleotide having the sequence (NxG4Ny)Q or (G4NxG4)Q wherein X is 1 to 8, Y is 1 to 8, and Q is 1 to 4, wherein said oligonucleotide modulates mammalian telomere length.
Dependencies are inferred from the claim text.